Molecular landscape of pancreatic cancer: challenges and clinical implications

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017).
  MedlineGoogle Scholar
• 2 Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14), 1473–1481 (2013).
  Medline CASGoogle Scholar
• 3 Yu Z, Zhong W, Tan ZM, Wang LY, Yuan YH. Gemcitabine adjuvant therapy for resected pancreatic cancer: a meta-analysis. Am. J. Clin. Oncol. 38(3), 322–325 (2015).
  MedlineGoogle Scholar
• 4 Kyrochristos ID, Glantzounis GK, Ziogas DE et al. From clinical standards to translating next-generation sequencing research into patient care improvement for hepatobiliary and pancreatic cancers. Int. J. Mol. Sci. 18(1), 180 (2017).
  MedlineGoogle Scholar
• 5 National Comprehensive Cancer Network, Inc. www.nccn.org/
  Google Scholar
• 6 Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57–74 (2012).
  MedlineGoogle Scholar
• 7 Le DT, Uram JN, Wang H et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 8 Nones K, Waddell N, Wayte N et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
  Medline CASGoogle Scholar
• 9 Humphris JL, Patch AM, Nones K et al. Hypermutation in pancreatic cancer. Gastroenterology 152(1), 68–74; e62 (2017).
  Medline CASGoogle Scholar
• 10 Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 16(7), e342–e351 (2015).
  Medline CASGoogle Scholar
• 11 Prat A, Pineda E, Adamo B et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl. 2), S26–S35 (2015).
  MedlineGoogle Scholar
• 12 Waddell N, Pajic M, Patch AM et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540), 495–501 (2015).
  Medline CASGoogle Scholar
• 13 Connor AA, Denroche RE, Jang GH et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 3(6), 774–783 (2017).
  MedlineGoogle Scholar
• 14 Bailey P, Chang DK, Nones K et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592), 47–52 (2016).
  Medline CASGoogle Scholar
• 15 Collisson EA, Sadanandam A, Olson P et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17(4), 500–503 (2011).
  Medline CASGoogle Scholar
• 16 Hoadley KA, Yau C, Wolf DM et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158(4), 929–944 (2014).
  Medline CASGoogle Scholar
• 17 Gundem G, Van Loo P, Kremeyer B et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547), 353–357 (2015).
  Medline CASGoogle Scholar
• 18 Eirew P, Steif A, Khattra J et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518(7539), 422–426 (2015).
  Medline CASGoogle Scholar
• 19 Yates LR, Gerstung M, Knappskog S et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21(7), 751–759 (2015).
  Medline CASGoogle Scholar
• 20 Hao JJ, Lin DC, Dinh HQ et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat. Genet. 48(12), 1500–1507 (2016).
  Medline CASGoogle Scholar
• 21 Zill OA, Greene C, Sebisanovic D et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 5(10), 1040–1048 (2015).
  Medline CASGoogle Scholar
• 22 Pishvaian MJ, Bender RJ, Matrisian LM et al. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget 8, 83446–83456 (2017).
  MedlineGoogle Scholar
• 23 Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discov. Today 22(8), 1148–1164 (2017).
  MedlineGoogle Scholar